Page last updated: 2024-12-08

isoxanthochymol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

isoxanthochymol: extract of Garcinia species; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GarciniagenusA plant genus of the family CLUSIACEAE. Members contain XANTHONES.[MeSH]ClusiaceaeThe mangosteen plant family (sometimes classified as Guttiferae; also known as Hypericaceae) of the order THEALES, subclass Dilleniidae, class Magnoliopsida. It includes trees and shrubs with resinous, sticky sap, usually with broad-ended, oblong, leathery leaves with a strong, central vein, flowers with many stamens.[MeSH]

Cross-References

ID SourceID
PubMed CID179605
MeSH IDM0505247

Synonyms (8)

Synonym
isoxanthochymol
52617-33-1
9h-4a,8-methano-2h-cycloocta(b)pyran-9,11-dione, 10-(3,4-dihydroxybenzoyl)-3,4,5,6,7,8-hexahydro-2,2,7,7-tetramethyl-3,6,8-tris(3-methyl-2-butenyl)-, (3r-(3alpha,4abeta,6alpha,8beta))-
nsc 741194
9h-4a,8-methano-2h-cycloocta(b)pyran-9,11-dione, 10-(3,4-dihydroxybenzoyl)-3,4,5,6,7,8-hexahydro-2,2,7,7-tetramethyl-3,6,8-tris(3-methyl-2-butenyl)-, (3r,4ar,6r,8s)-
(9r,11r)-7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9,11-tris(3-methylbut-2-enyl)-5-oxatricyclo[7.3.1.01,6]tridec-6-ene-8,13-dione
10-(3,4-dihydroxybenzoyl)-2,2,7,7-tetramethyl-3,6,8-tris(3-methylbut-2-en-1-yl)-3,4,5,6,7,8-hexahydro-2h,9h-4a,8-methanocycloocta[b]pyran-9,11-dione
DTXSID50967053
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (66.67)29.6817
2010's2 (22.22)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]